Vitamin C and corticosteroids in viral pneumonia

Matthew Harry Anstey; Jacky Luu; Erina Myers; Robert N Palmer; Bradley Wibrow; Kwok M Ho

doi:10.4266/acc.2020.01081

Articles

Page Path: HOME > Acute Crit Care > Volume 36(2); 2021 > Article

Letter to the Editor Pulmonary Vitamin C and corticosteroids in viral pneumonia: Acute and Critical Care 2021;36(2):169-171.
DOI: https://doi.org/10.4266/acc.2020.01081
Published online: March 10, 2021

Matthew Harry Anstey^1,2

, Jacky Luu¹, Erina Myers¹, Robert N Palmer^1,2, Bradley Wibrow^1,2, Kwok M Ho^2,3

¹Department of Intensive Care, Sir Charles Gairdner Hospital, Perth, Australia

²University of Western Australia School of Medicine, Perth, Australia

³Department of Intensive Care, Royal Perth Hospital, Perth, Australia

Corresponding author Matthew Harry Anstey Department of Intensive Care, Sir Charles Gairdner Hospital, Hospital Avenue, Perth 6009, Australia Tel: +61-864571010 Fax: +61-864571010 E-mail: matthew.anstey@health.wa.gov.au

• Received: December 4, 2020 • Revised: February 9, 2021 • Accepted: February 13, 2021

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

9,376 Views
141 Download
2 Web of Science
1 Crossref
2 Scopus

prev next

Full Article

Download PDF

NOTES
REFERENCES

Dear Editor:

The current coronavirus disease 2019 (COVID-19) pandemic has re-ignited interest in using adjunctive agents—including corticosteroids and vitamin C—to attenuate the severity of viral pneumonia and acute lung injury [1,2]. Although the efficacy of dexamethasone on COVID-19 seems convincing, the role of corticosteroids with and without vitamin C in other viral pneumonia remains contentious and unclear. We hypothesised that high dose intravenous vitamin C (6 g/day) used in conjunction with corticosteroids could improve oxygenation in non–COVID-19 viral pneumonia.

The 2019 winter season was expected to have a significant outbreak of influenza pneumonia, and in planning for this, the intensive care unit (ICU) clinicians at the Sir Charles Gairdner Hospital decided that based on the favourable safety profile and potential benefit of vitamin C, it could be provided to any patients with presumed severe viral pneumonia based on the combination of the prodromal symptoms, acute onset, and bilateral (non-consolidative) infiltrates on chest X-rays, at the discretion of the treating clinician. Intravenous vitamin C (Rotexmedica, Trittau, Germany; 1.5 g four times a day [qid] for 72 hours) was administered within 12 hours of admission. The dose was extrapolated from that used in previous studies [3]. Hydrocortisone (50 mg qid) was also given for those who vasopressor-dependent shock until clinical improvement. The patients with presumed viral pneumonia who were not given either vitamin C or corticosteroids were used as a comparator group. Hypothesising that, if vitamin C was to have an effect on oxygenation, it would occur within 24 hours, the primary outcome was difference in arterial oxygen tension (PaO2) to inspired oxygen concentration (FiO2) ratio (P/F ratio) in the 24 hours following the administration of vitamin C. Secondary outcomes were mortality, length of mechanical ventilation and ICU stay. Study design and data collection was prospective.

Table 1 outlines the demographic and clinical characteristics of the 16 patients. There was no significant difference in Acute Physiology and Chronic Health Evaluation (APACHE) II between groups receiving corticosteroids or vitamin C. Nine and seven patients were invasively and noninvasively ventilated, respectively, 11 (69%) required vasopressor support, 9 (56%) received vitamin C, 11 (69%) received corticosteroids, and 7 (44%) received both agents. Influenza A, influenza B and respiratory syncytial virus were detected by viral polymerase chain reaction in seven, one, and four patients, respectively. Fourteen patients (88%) received oseltamivir, and seven patients had concomitant bacterial or fungal pathogens detected in their sputum samples and were treated accordingly.

There was no statistically significant difference in the P/F ratio in the first 24 hours between those who received and not received vitamin C. The P/F ratios within the first 24 hours between those who received both vitamin C and corticosteroids and those who did not receive both agents were also not significantly different (P = 0.860), but the post-hoc comparison of PF ratios between the two groups at 24 hours were significantly different (P = 0.039) (Figure 1). Five patients (31%) died in hospital and there was a significant difference in survival between those who received corticosteroids (10/11 survived) and those who did not (1/5, unadjusted chi-square test: P = 0.001; after adjustment by multiple permutations: chi-square test: 8.045, P = 0.012), whereas use of vitamin C alone (6/9 survived) or both agents (6/7 survived) did not reach significance in survival compared to no vitamin C or not using both agents, respectively. Length of mechanical ventilation or duration of ICU stay was not statistically different between the groups received both vitamin C and corticosteroids, and without both, or between patients received vitamin C alone and those without vitamin C.

This small prospective cohort study showed that corticosteroids may be useful for patients with viral pneumonia other than COVID-19 [1], and administration of vitamin C alone did not improve oxygenation in patients with viral pneumonia, consistent with previous studies [4]. It is possible that a higher dose of vitamin C may offer more benefits than the dose that we used, or it works only when combined with corticosteroids as shown in our post-hoc analysis [5]. Nonetheless, this was not a randomised-controlled study and our results could be, at least in part, explained by type I error and confounding. Furthermore, the viral pathogens were not the same for all patients, making generalisability difficult. In summary, our results showed that corticosteroids might also be effective for viral pneumonia other than COVID-19, but vitamin C was not. However, an adequately powered randomised-controlled trial is needed to assess whether adding vitamin C to corticosteroids will improve oxygenation in viral pneumonia.

Approval for the study was granted as a quality improvement project for monitoring of outcomes of patients with presumed viral pneumonia admitted to the intensive care (SCGH # 32985), with a waiver for ethics approval.

NOTES

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

Figure 1.

Comparison in PaO₂/FiO₂ ratio over time (at baseline, 6 hours, and 24 hours) between the groups who received vitamin C (Vit C) and corticosteroids and those who did not for viral pneumonia. PaO₂: arterial oxygen tension; FiO₂: inspired oxygen concentration.

Table 1.

Characteristics of the patients

Variable	Value (n=16)
Age (yr)	67 (58–80)
Female sex	7 (44)
APACHE II score	18.5 (13.3–22.8)
Comorbidity
COPD	4
Immunosuppressed/active cancer	3
Number of quadrants with infiltrates on chest X-ray	2 (0–3)
FiO₂ before initiation of vitamin C (%)	50 (43–60)
PaO₂ before initiation of vitamin C (mm Hg)	86 (73–115)
PaO₂/FiO₂ ratio before initiation of vitamin C (mm Hg)	173 (135–251)
Length of invasive mechanical ventilation (hr)^a	216 (96–444)
Requiring vasopressors	11 (69)
Requiring renal replacement therapy	4 (25)
Treated with IV hydrocortisone	11 (69)
Treated with high-dose vitamin C	9 (56)
Treated with both hydrocortisone and vitamin C	7 (44)
Treated with oseltamivir	14 (88)
Viral organism confirmed on nasal polymerase chain reaction
Influenza A	7 (44)
Influenza B	1 (6)
Respiratory syncytial virus	4 (25)
Negative	3 (19)
Not obtained (before death)	1 (6)
Coexisting non-viral organisms in sputum or blood^b
Gram positive bacteria (Enterococcus)	1 (6)
Gram negative bacteria (Haemophilus, Pseudomonas, Klebsiella, Escherichia coli)	4 (25)
Non-bacterial including fungal (e.g., Candida species and Aspergillus)	5 (31)
Not identified	9 (56)
Comorbidity
Chronic obstructive airway disease/asthma	4 (25)
Immunosuppressed (with active cancer or chemotherapy)	2 (13)
Hospital mortality	5 (31)

Values are presented as mean (interquartile range) or number (%).

APACHE: Acute Physiology and Chronic Health Evaluation; COPD: chronic obstructive pulmonary disease; FiO₂: inspired oxygen concentration; PaO₂: arterial oxygen tension.

^aOnly data from nine patients who were invasively ventilated were included; six patients treated with only noninvasive ventilation and also one treated only with high flow nasal oxygen were not included;

^bSome patients had more than one type of coexisting organisms isolated.

REFERENCES

1. Recovery Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384:693-704.Article PubMed
2. Fisher BJ, Seropian IM, Kraskauskas D, Thakkar JN, Voelkel NF, Fowler AA 3rd, et al. Ascorbic acid attenuates lipopolysaccharide-induced acute lung injury. Crit Care Med 2011;39:1454-60.Article PubMed
3. Zabet MH, Mohammadi M, Ramezani M, Khalili H. Effect of high-dose ascorbic acid on vasopressor’s requirement in septic shock. J Res Pharm Pract 2016;5:94-100.Article PubMed PMC
4. Fowler AA 3rd, Truwit JD, Hite RD, Morris PE, DeWilde C, Priday A, et al. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA 2019;322:1261-70.Article PubMed PMC
5. Fowler Iii AA, Kim C, Lepler L, Malhotra R, Debesa O, Natarajan R, et al. Intravenous vitamin C as adjunctive therapy for enterovirus/rhinovirus induced acute respiratory distress syndrome. World J Crit Care Med 2017;6:85-90.Article PubMed PMC

Figure & Data

References

Citations

Citations to this article as recorded by

Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review
Duygu Ağagündüz, Menşure Nur Çelik, Merve Esra Çıtar Dazıroğlu, Raffaele Capasso
Nutrients.2021; 13(5): 1550. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Vitamin C and corticosteroids in viral pneumonia

Acute Crit Care. 2021;36(2):169-171. Published online March 10, 2021

DOI: https://doi.org/10.4266/acc.2020.01081

XML Download

Figure

Vitamin C and corticosteroids in viral pneumonia

Figure 1. Comparison in PaO2/FiO2 ratio over time (at baseline, 6 hours, and 24 hours) between the groups who received vitamin C (Vit C) and corticosteroids and those who did not for viral pneumonia. PaO2: arterial oxygen tension; FiO2: inspired oxygen concentration.

Figure 1.

Vitamin C and corticosteroids in viral pneumonia

Variable	Value (n=16)
Age (yr)	67 (58–80)
Female sex	7 (44)
APACHE II score	18.5 (13.3–22.8)
Comorbidity
COPD	4
Immunosuppressed/active cancer	3
Number of quadrants with infiltrates on chest X-ray	2 (0–3)
FiO₂ before initiation of vitamin C (%)	50 (43–60)
PaO₂ before initiation of vitamin C (mm Hg)	86 (73–115)
PaO₂/FiO₂ ratio before initiation of vitamin C (mm Hg)	173 (135–251)
Length of invasive mechanical ventilation (hr)^a	216 (96–444)
Requiring vasopressors	11 (69)
Requiring renal replacement therapy	4 (25)
Treated with IV hydrocortisone	11 (69)
Treated with high-dose vitamin C	9 (56)
Treated with both hydrocortisone and vitamin C	7 (44)
Treated with oseltamivir	14 (88)
Viral organism confirmed on nasal polymerase chain reaction
Influenza A	7 (44)
Influenza B	1 (6)
Respiratory syncytial virus	4 (25)
Negative	3 (19)
Not obtained (before death)	1 (6)
Coexisting non-viral organisms in sputum or blood^b
Gram positive bacteria (Enterococcus)	1 (6)
Gram negative bacteria (Haemophilus, Pseudomonas, Klebsiella, Escherichia coli)	4 (25)
Non-bacterial including fungal (e.g., Candida species and Aspergillus)	5 (31)
Not identified	9 (56)
Comorbidity
Chronic obstructive airway disease/asthma	4 (25)
Immunosuppressed (with active cancer or chemotherapy)	2 (13)
Hospital mortality	5 (31)

Table 1. Characteristics of the patients

Values are presented as mean (interquartile range) or number (%).

APACHE: Acute Physiology and Chronic Health Evaluation; COPD: chronic obstructive pulmonary disease; FiO₂: inspired oxygen concentration; PaO₂: arterial oxygen tension.

Only data from nine patients who were invasively ventilated were included; six patients treated with only noninvasive ventilation and also one treated only with high flow nasal oxygen were not included;

Some patients had more than one type of coexisting organisms isolated.